This article is more than 5 years old. Information may no longer be current.

VIDEO: Plenary abstract ‘very impactful’ for patients with FLT3-mutated AML

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ORLANDO, Fla. — Ruben A. Mesa, MD, offers his reaction to a plenary abstract from the ASH Annual Meeting and Exposition that showed the addition of midostaurin to standard induction chemotherapy prolonged survival in younger adults with FLT3-mutated acute myeloid leukemia.